Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases

BACKGROUND: Comorbid diseases influence patient outcomes, yet little is known about how comorbidities interact with treatments for metastatic castrate-resistant prostate cancer (mCRPC). No head-to-head trials have compared the efficacy of abiraterone and enzalutamide - oral androgen-receptor targete...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoen, Martin W., Carson, Kenneth R., Eisen, Seth A., Bennett, Charles L., Luo, Suhong, Reimers, Melissa A., Knoche, Eric M., Whitmer, Alison L., Yan, Yan, Drake, Bettina F., Sanfilippo, Kristen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638085/
https://www.ncbi.nlm.nih.gov/pubmed/36104504
http://dx.doi.org/10.1038/s41391-022-00588-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638085/
https://www.ncbi.nlm.nih.gov/pubmed/36104504
http://dx.doi.org/10.1038/s41391-022-00588-5

Ejemplares similares